Recent

% | $
Quotes you view appear here for quick access.

SAVİENT PHARM AŞ Message Board

  • halap2 halap2 Aug 23, 2013 2:51 AM Flag

    Research for application KRYSTEXXA to KIDNEY DISASE and DIALYSIS

    I believe that A Research for application KRYSTEXXA to KIDNEY DISASE and DIALYSIS is going to be increase stock price well over $35

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Publication of Research results for application of KRYSTEXXA to KIDNEY DISEASE and DIALYSIS results may be public in any day.

    • IMO Research for application of KRYSTEXXA to KIDNEY DISEASE and DIALYSIS is on progress, BUYOUT price should not be less than $35.

    • Expected announcements as listed below in hours, days or week, IMO these announcements are going to cause a great upside correction stock price, it is just my opinion.

      Announced additional new data demonstrating KRYSTEXXA-treated refractory chronic gout patients experienced significantly improved health-related quality of life
      Announced new data from an open-label extension (OLE) study published in the Annals of the Rheumatic Diseases reinforcing the safety and efficacy profile of KRYSTEXXA
      Announced the elections of Robert G. Savage and Dr. David Meeker to the Company's board of directors
      Completed study of KRYSTEXXA in dialysis patients, and anticipate data to be presented at a major scientific meeting later this year
      Received European Commission marketing authorization in January 2013 for KRYSTEXXA® for the treatment of certain patients with chronic tophaceous gout in the EU
      Announced a co-promotion agreement with Swedish Orphan Biovitrum AB (Sobi) for Kineret® (anakinra) in the U.S.

    • IMO, application of KRYSTEXXA to KIDNEY DISEASE and DIALYSIS is going to be increase stock price well over $35

    • In my opinion KIDNEY DISEASE and DIALYSIS label expansion is on progress

    • I am expect a few good announcement as listed below in coming weeks, do know if they will cause any upside correction stock price, but am very positive about that, anyway it is just my opinion, could be wrong.

      Announced additional new data demonstrating KRYSTEXXA-treated refractory chronic gout patients experienced significantly improved health-related quality of life
      Announced new data from an open-label extension (OLE) study published in the Annals of the Rheumatic Diseases reinforcing the safety and efficacy profile of KRYSTEXXA
      Announced the elections of Robert G. Savage and Dr. David Meeker to the Company's board of directors
      Completed study of KRYSTEXXA in dialysis patients, and anticipate data to be presented at a major scientific meeting later this year
      Received European Commission marketing authorization in January 2013 for KRYSTEXXA® for the treatment of certain patients with chronic tophaceous gout in the EU
      Announced a co-promotion agreement with Swedish Orphan Biovitrum AB (Sobi) for Kineret® (anakinra) in the U.S.

    • I think SOBI already made a great offer to buy SAVIENT.

    • Papers on KRYSTEXXA to KIDNEY DISASE and DIALYSIS should be around fst week of Oct.

    • I am agree with your statmant. It should have a major effect on stock price

    • Halap, agree that Research results for application KRYSTEXXA to KIDNEY DISASE and DIALYSIS may make a huge differences on stock prices.

    • View More Messages